Loading…
Gujarat Themis Biosyn (GUJTHEM)₹379.65−1.12%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Gujarat Themis Biosyn reported sales of ₹43.90 Cr, up 22.3% from Jun 2025, and net profit of ₹11.01 Cr, up 22.5% year on year. For the year to Mar 2026, sales were ₹165 Cr and net profit ₹46.95 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Jun 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Sales | 35.89 | 43.86 | 43.90 |
| Expenses | 22.01 | 25.03 | 23.01 |
| Operating Profit | 14.01 | 19.03 | 21.02 |
| OPM % | 39.0% | 44.0% | 48.0% |
| Other Income | 0.00 | 0.99 | 0.00 |
| Interest | 0.00 | 1.99 | 1.99 |
| Depreciation | 1.99 | 3.98 | 3.98 |
| Profit before tax | 11.99 | 13.98 | 14.97 |
| Tax % | 25.0% | 24.0% | 27.0% |
| Net Profit | 8.99 | 10.99 | 11.01 |
| EPS (Rs) | 0.84 | 1.01 | 1.03 |
| Mar 2026 | |
|---|---|
| Sales | 165 |
| Expenses | 90.10 |
| Operating Profit | 76.11 |
| OPM % | 46.0% |
| Other Income | 1.99 |
| Interest | 2.99 |
| Depreciation | 12.94 |
| Profit before tax | 61.92 |
| Tax % | 25.0% |
| Net Profit | 46.95 |
| EPS (Rs) | 4.29 |
| Dividend payout % | 0.0% |
For the Jun 2026 quarter, Gujarat Themis Biosyn reported sales of ₹43.90 Cr, up 22.3% year on year and net profit of ₹11.01 Cr, up 22.5% year on year. The operating margin was 48.0%.
Gujarat Themis Biosyn's sales for the year to Mar 2026 were ₹165 Cr.
Net profit for the year to Mar 2026 was ₹46.95 Cr. Earnings per share over the same trailing period were ₹4.29.